Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
19 Ottobre 2023 - 2:30PM
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced that Andreas
Grauer, M.D., has been named Omeros’ chief medical officer. In his
new role, Dr. Grauer will be responsible for guiding all clinical
activities globally for the company, including clinical development
and operations, medical affairs, safety, and biometrics. A highly
tenured physician, scientist and pharmaceutical leader, Dr. Grauer
brings to Omeros over 20 years of industry experience across a
broad range of therapeutic areas including inflammation,
nephrology, oncology, neurology, endocrinology, and metabolism.
“We are very pleased to welcome Andreas to Omeros’ leadership
team,” said Gregory A. Demopulos, M.D., chairman and chief
executive officer of Omeros. “Andreas brings tremendous depth and
breadth of clinical leadership expertise, a proven track record of
worldwide BLA and NDA approvals, and a strategic approach to
pipeline and product development that includes successful
management of complex global alliances. I am confident that Andreas
will deliver for our organization as we seek to maximize the value
of our extensive development pipeline.”
With more than two decades overseeing development programs
spanning phases 1b, 2, 3, and 4, resulting in multiple BLA and NDA
approvals in US, Canada, Europe, and Japan as well as lifecycle
management, Dr. Grauer has served in leadership roles at both large
and small biopharmaceutical companies. He joins Omeros from
Federation Bio where, as chief medical officer, he led all clinical
activities with a focus on hyperoxaluria and immuno-oncology. Prior
to that, Dr. Grauer was chief medical officer at Corcept
Therapeutics, leading its global development organization in the
design and execution of phase 1 through phase 3 clinical programs
in oncology, neurology, endocrinology, and metabolism indications.
Before his time at Corcept, Dr. Grauer held several roles of
increasing responsibility at Amgen, most recently serving as vice
president of global development, therapeutic area head, and
co-chair of the franchise steering committee for bone, nephrology
and inflammation. While in that role, he was responsible for
franchise strategy and four global filings across multiple
therapeutic areas. Earlier in his career, Dr. Grauer was at Proctor
and Gamble Pharmaceuticals where he held roles as global executive
medical director for bone and for new technology development.
“I am excited to join the leadership team at Omeros,” said Dr.
Grauer. “The strength of the team, together with our leading
franchise of complement inhibitors in late-stage development and
innovative earlier-stage assets, present outstanding opportunities
to improve the lives of patients while delivering significant value
for shareholders. I look forward to leading Omeros’ clinical
development efforts and to contributing to the Company’s
success.”
Dr. Grauer received his medical degree from the University of
Heidelberg Medical School, Germany, where he also completed his
medical training in internal medicine and endocrinology. He did
research in molecular and cellular endocrinology both there and
during a post-doctoral fellowship at Baylor College of Medicine. He
holds an active associate professorship of medicine at the
University of Heidelberg Medical School and has authored over 120
publications in top-tier journals.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
COVID-19. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently
in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3,
the key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
Forward-Looking Statements
This press release contains “forward-looking statements” as that
term is defined in the Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, these statements are often
identified by the words “may”, “might”, “believes”, “thinks”,
“anticipates”, “plans”, “expects”, “intends” or similar
expressions. These forward-looking statements include, but are not
limited to, expectations regarding the performance and anticipated
contributions of newly-hired personnel. Such forward-looking
statements are based on current information available to the
Company and involve inherent risks and uncertainties, including
factors that could delay, divert or change any such forward-looking
statements, and could cause actual outcomes and results to differ
materially from current expectations. No forward-looking statement
can be guaranteed. In addition, such risks and uncertainties may
include those described in the Company’s annual, quarterly and
current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed
or furnished with the SEC, which are available at the Company’s
website (www.omeros.com) under “Investors & News”. You are
cautioned not to place undue reliance on any forward-looking
statements as there are important factors that could cause actual
results to differ materially from those in any forward-looking
statements, many of which are beyond our control. Except to the
extent required by law, the Company undertakes no obligation to
publicly update any forward-looking statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231019539719/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations IR@omeros.com
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Omeros (NASDAQ:OMER)
Storico
Da Giu 2023 a Giu 2024